The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II, open-label study of erlotinib (ERL) in patients with NSCLC with activating mutations of the EGFR identified on tissue samples, plasma DNA, and CTC-trigger.
Lucio Crino
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Antonio Chella
No relevant relationships to disclose
Fausto Barbieri
No relevant relationships to disclose
Paola Venturino
No relevant relationships to disclose
Antonio Marchetti
No relevant relationships to disclose
Michele Milella
No relevant relationships to disclose
Ariela Brandes
No relevant relationships to disclose
Tommaso De Pas
No relevant relationships to disclose